Objectives This study sought to validate the ability of the VerifyNow P2Y12 assay (Accumetrics, San Diego, California) in predicting both ischemic and bleeding events after elective percutaneous coronary intervention (PCI).
Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the pharmacological treatment of patients with coronary artery disease undergoing elective percutaneous coronary intervention (PCI). However, a wide interindividual variability in response to clopidogrel therapy has been described (1) (2) (3) (4) , implying that a substantial proportion of patients have inadequate platelet inhibition (either too high or too low) at the time of PCI.
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In patients with a decreased response to clopidogrel, high platelet reactivity (HPR) may result in increased risk of thrombotic complications after PCI (5) (6) (7) (8) (9) (10) (11) . On the other hand, in patients with increased response to clopidogrel, low platelet reactivity (LPR) may result in increased risk of bleeding complications (12, 13) . Various attempts have been made to identify patients with inadequate platelet reactivity through the use of different platelet function tests (14, 15) . Using the VerifyNow P2Y12 assay (Accumetrics, San Diego, California), several studies have shown that platelet reactivity above a threshold of Ϸ240 P2Y 12 reaction units (PRU) is associated with an increase in both shortand long-term ischemic adverse events (8, 9, 11, 16, 17) , whereas PRU values Յ189 are associated with higher risk of early major bleeding or entry-site complications after PCI (13) . Overall, these data suggest the possibility of identifying a therapeutic window for platelet reactivity, measured with the VerifyNow P2Y12 assay, associated with the lowest risk for both thrombotic and bleeding complications.
Therefore, we aimed to validate the ability of the VerifyNow P2Y12 assay in predicting both ischemic and bleeding events after elective PCI in patients on dual antiplatelet therapy.
Methods
Patient population and study design. The ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) is a prospective study enrolling consecutive patients with stable angina and established coronary artery disease undergoing elective PCI from April 2010 to February 2011 at the Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy, and at the Cardiovascular Center Aalst, Aalst, Belgium. All patients received clopidogrel, either a 600-mg loading dose Ն6 h before intervention or a maintenance dose of 75 mg/day for at least 5 days. Patients on chronic treatment did not receive any further loading dose of clopidogrel. Technicalities of the procedure, including use of the radial approach, drugeluting stents, and glycoprotein IIb/IIIa inhibitors, were left to the operator's discretion. Procedural anticoagulation consisted of unfractionated heparin administrated to achieve an activated clotting time of 250 to 300 s. Procedural success was defined as a reduction in percent diameter stenosis to below 30% in the presence of Thrombolysis In Myocardial Infarction (TIMI) flow grade 3 in the main vessel and all side branches Ն2 mm in diameter. After PCI, patients receiving bare-metal stents received clopidogrel 75 mg/day for at least 4 weeks, whereas those receiving drug-eluting stents received clopidogrel for 12 months. All patients were on aspirin treatment before intervention and continued aspirin (80 to 100 mg/day) indefinitely. Exclusion criteria were upstream use of glycoprotein IIb/IIIa inhibitors, treatment with oral anticoagulant drugs, platelet count Ͻ70 ϫ 10 9 /l, high bleeding risk (active internal bleeding, history of hemorrhagic stroke, intracranial neoplasm, arteriovenous malformation or aneurysm, ischemic stroke in the previous 3 months), coronary artery bypass surgery in the previous 3 months, and severe renal failure (serum creatinine Ͼ2 mg/dl). After PCI, patients receiving bare-metal stents received clopidogrel 75 mg/day for at least 4 weeks, whereas those receiving drug-eluting stents received clopidogrel for at least 12 months. Clinical follow-up data were obtained at 30 days following an office visit, a telephone interview, or after chart review. All events were classified and adjudicated by a physician not involved in the follow-up process. This study complied with the Declaration of Helsinki and was approved by the local ethics committees, with all patients giving written informed consent. Blood sampling and platelet function analysis. Platelet reactivity was measured in the catheterization laboratory using the VerifyNow P2Y12 assay immediately before PCI. Blood was drawn from the femoral or radial artery immediately after sheath insertion. After discarding the first 5 ml of blood, a further sample was collected into a 2-ml tube containing 3.2% sodium citrate. The VerifyNow P2Y12 assay is a validated optical turbidimetric point-of-care assay specifically assessing the effects of P2Y 12 receptor blockers (18, 19) . Results are expressed as PRU: the lower the PRU value, the higher the platelet aggregation inhibition, and vice versa. In all cases, the operators were blinded to the results of the platelet function analysis. Mangiacapra et al. Therapeutic Window for Platelet Reactivity Pre-PCI Blood samples were drawn before, at 8 and 24 h after intervention for the assessment of creatine kinase-myocardial band (CK-MB), and thereafter if clinically indicated. Measurements of CK-MB levels were performed by Access 2 Immunochemiluminometric assay (Beckman Coulter, Fullerton, California), and the upper limit of normal was 4 ng/ml. Endpoints and definitions. The primary endpoint of this study was the 30-day incidence of net adverse clinical events (NACE), defined as the occurrence of ischemic events or bleeding events, in relation to the PRU distribution. To evaluate the impact of pre-PCI platelet aggregation on the primary outcome measure, we stratified the study population according to their platelet aggregation value using cutoff points derived from receiver-operating characteristic (ROC) curve analysis. Patients with PRU values below the optimal cutoff for bleeding events were classified as having LPR; patients with PRU values above the optimal cutoff for ischemic events were classified as having HPR; the remaining patients with PRU values between the aforementioned cutoff point were classified as having normal platelet reactivity (NPR).
Secondary endpoints were: 1) the occurrence of the single components of the primary endpoint in relation to the PRU distribution; and 2) platelet reactivity according to the occurrence of outcome measures.
Ischemic events were defined as death, myocardial infarction (MI), or target vessel revascularization (TVR). MI included both periprocedural and spontaneous events. Periprocedural MI was defined as a post-procedural increase in CK-MB Ն3 times the 99th percentile of the upper reference limit for patients with baseline negative myocardial necrosis markers, according to the Joint European Society of Cardiology/ American College of Cardiology Foundation/American Heart Association/World Heart Federation task force consensus statement on the redefinition of MI for clinical trials on coronary intervention (20) . In patients with increased baseline levels of CK-MB, a subsequent increase Ն50% the baseline value fulfilled the criteria for periprocedural MI (21) . Occurrence of spontaneous MI, defined as the presence of symptoms compatible with recurrent ischemia associated with electrocardiographic changes indicative of new ischemia (new ST-T changes or new left bundle branch block) (20) was also registered. Definite stent thrombosis (ST) was defined according to the Academic Research Consortium definition (22) . TVR was clinically driven and included bypass surgery or repeat PCI of the target vessel(s). Bleeding events were defined as major bleeding according to the TIMI criteria (23), or large entry-site hematoma (Ͼ10 cm in diameter) (13) . Entry-site hematomas were repeatedly monitored throughout the hospitalization, and the largest size detected was used for the analysis. Statistics. In the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during AngioplastyPlatelet Reactivity Predicts Outcome) study (9), the 30-day incidence of ischemic events in patients with PRU values Ն240 was 15.0%, whereas in the ARMYDA-BLEEDS (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study) (13), the 30-day incidence of bleeding events was 11.6% in patients with pre-PCI PRU values Յ189. Assuming that patients falling Figure 1 . Distribution of Platelet Reactivity PRU ϭ P2Y 12 reaction units.
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Therapeutic Window for Platelet Reactivity Pre-PCI in the NPR group represent one-third of the entire population, and expecting in these patients a 50% reduction in the occurrence of NACE, compared with patients in the LPR and HPR groups, a total of at least 700 patients were needed to detect the expected difference with an estimated power of 80% at a 2-sided alpha of 0.05.
Continuous variables are expressed as mean Ϯ SD or as median [interquartile range], as appropriate, whereas categorical variables are reported as frequencies and percentages. Comparisons between continuous variables were performed using the Student t test or Mann-Whitney U test. Comparisons between categorical variables were evaluated using the Fisher exact test or the Pearson chi-square test, where appropriate. Normal distribution of PRU levels in the study population was confirmed by Kolmogorov-Smirnov test. A ROC curve analysis was used to test the ability of PRU values to discriminate between patients with and without ischemic events, and with and without bleeding events at 30 days. The optimal cutoff point was calculated by determining the value that provided the greatest sum of sensitivity and specificity. All clinical and procedural features, as well as pre-PCI platelet reactivity groups, were evaluated in a univariate analysis for the association with 30-day NACE using logistic regression. Only variables with a p value Ͻ0.15 were then entered into the final multivariable logistic regression model providing odds ratios (ORs) and 95% confidence intervals (CI). Statistical analysis was performed using Stata/IC version 10.0 (STATA Corp., College Station, Texas), and p values Ͻ0.05 (2-tailed) were considered significant.
Results
Study population. A total of 732 patients were recruited into the study. The distribution of platelet reactivity is shown in Figure 1 . Clinical and procedural features are listed in Tables 1 and 2 , respectively. Diabetes mellitus was more frequent among patients with HPR, who also more frequently had multivessel disease. Procedural success was achieved in all patients. In 23 patients, a flow-limiting vessel HPR ϭ high platelet reactivity; LPR ϭ low platelet reactivity; NPR ϭ normal platelet reactivity; PRU ϭ P2Y 12 reaction units. 
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Ն239 was the optimal cutoff point to predict ischemic events, with a sensitivity of 63%, specificity of 70%, a negative predictive value (NPV) of 96%, and a positive predictive value (PPV) of 15% ( Fig. 2A) . Similarly, pre-PCI PRU values could significantly discriminate between patients with and without bleeding events (AUC: 0.72; 95% CI: 0.65 to 0.80; p Ͻ 0.0001). A PRU value Յ178 was the optimal cutoff point to predict bleeding events, with a sensitivity of 78%, specificity of 63%, a NPV of 98%, and a PPV of 10% (Fig. 2B) . On the basis of these results, we divided our study population into 3 groups based on the distribution of PRU values: LPR (PRU Յ178; n ϭ 248 [33.9%]), NPR (PRU between 179 and 238; n ϭ 244 [33.3%]), and HPR (PRU Ն239; n ϭ 240 [32.8%]).
The incidence of NACE was 14.1% in the LPR group, 7.8% in the NPR group (p ϭ 0.025 vs. LPR group), and 15.4% in the HPR group (p ϭ 0.005 vs. NPR group) (Fig. 3) . Considering patients with LPR and HPR together, the incidence of NACE was 14.8% (p ϭ 0.007 vs. NPR group). PRU values in the LPR or HPR group could predict the occurrence of NACE with a sensitivity of 79%, a specificity of 35%, a NPV of 92%, a PPV of 15%, and an overall prognostic accuracy of 41%. Secondary endpoints. Patients in the LPR, NPR, and HPR groups presented an incidence of ischemic events of 4.0%, 4.9%, and 15.0%, respectively (p for trend Ͻ0.0001) (Fig. 4A) , and an incidence of bleeding events of 10.5%, 2.9%, and 1.3%, respectively (p for trend Ͻ0.0001) (Fig. 4B) . The incidence of the single components of the primary endpoint according to PRU groups is reported in Figure 4 . The incidence of death was overall low and similar in the 3 study groups (0.4%). Patients in the HPR group showed the highest incidence of MI (p for trend Ͻ0.001) (14) 30 (12) 33 (14) 43 (18) (2) 3 (1) 4 (2) 4 (2) 0.897
Radial access 29 (4) 12 (5) 8 (3) 9 (4) (93) 225 (92) 225 (94) 7-F 51 (7) 17 (7) 19 (8) 15 (6) Bailout use of glycoprotein IIb/IIIa inhibitors 44 (6) 19 (7) 11 (5) 14 (6) 0.335
Values are n (%), mean Ϯ SD, or median [interquartile range].
Abbreviations as in Table 1 .
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Therapeutic Window for Platelet Reactivity Pre-PCI and TVR (p for trend ϭ 0.041). Periprocedural MI occurred in 3.2%, 4.5%, and 13.3% of patients with LPR, NPR, and HPR, respectively (p for trend Ͻ0.001). Spontaneous MI occurred in 0.4%, 0.0%, and 2.1% of patients with LPR, NPR, and HPR, respectively (p for trend ϭ 0.041). ST occurred in 4 patients (1.7%) in the HPR group and in none of the LPR or NPR groups (p for trend ϭ 0.013). Patients in the LPR group showed the highest incidence of major bleeding (p for trend ϭ 0.003) and hematoma Ͼ10 cm (p for trend Ͻ0.001).
The average pre-PCI platelet reactivity was 207 Ϯ 73 PRU in the overall population, and 206 Ϯ 72 PRU in patients without adverse events at 30-day follow-up. Patients experiencing bleeding events had the lowest PRU values (154 Ϯ 59, p Ͻ 0.0001 vs. patients without events), whereas patients experiencing ischemic events had the highest PRU values (247 Ϯ 67, p Ͻ 0.0001 vs. patients without events) (Fig. 5) . Multivariate analysis. At univariate analysis, diabetes mellitus, multivessel disease, chronic renal failure, total stent length, use of glycoprotein IIb/IIIa inhibitors, and PRU values in the NPR range were significantly associated with the occurrence of NACE. Multivariate analysis (Table 3) showed that PRU values in the NPR range were an independent predictor of decreased risk of NACE (OR: 0.47, 95% CI: 0.27 to 0.81).
Discussion
In the present study, we have identified a therapeutic window for platelet reactivity, as measured by the VerifyNow P2Y12 assay, in patients with stable angina undergoing elective PCI. Those patients with PRU values within this therapeutic window accounted for one-third of our patients and had the lowest risk for the combined endpoint of ischemic and bleeding complications, 30 days after elective PCI. Of note, PRU values between 179 and 238 resulted in almost a 50% risk reduction for NACE compared with patients with either low or high platelet reactivity.
Given the wide interindividual variability in response to clopidogrel (4), platelet reactivity is highly heterogeneous in the overall population of patients on dual antiplatelet therapy, and follows a normal Gaussian distribution (Fig. 1) . Therefore, it ranges from low levels on one extreme of its bell-shaped distribution to high levels on the other extreme. Several studies have shown that patients who have high platelet reactivity before PCI are at increased risk of ischemic events despite taking dual antiplatelet therapy (5-11). Several attempts have been made to identify optimal thresholds of platelet reactivity in order to stratify those patients at risk of ischemic events following PCI (14, 15) . Among the many commercially available platelet function tests, the VerifyNow P2Y12 assay has proven to be particularly useful. Not only is it an effective tool for identifying high platelet reactivity in patients taking dual antiplatelet therapy using a threshold of Ϸ240 PRU, but knowing this information helps to predict which patients will experience an ischemic event (8, 9, 11, 16, 17, 24) . Consistent with these studies, we also found a very similar optimal cutoff value to predict ischemic events in our population of patients undergoing elective PCI ROC analysis for bleeding events. PRU values are in the opposite direction for the 2 curves. AUC ϭ area under the curve; CI ϭ confidence interval; NPV ϭ negative predictive value; PPV ϭ positive predictive value; PRU ϭ P2Y 12 reactivity unit. N T I O N S , V O L . 5 , N O . 3 , 2 0 1 2   M A R C H 2 0 1 2 : 2 8 1 -9 Mangiacapra et al. Therapeutic Window for Platelet Reactivity Pre-PCI with a PRU value of Ն239. Our data also corroborate the hypothesis that a threshold effect exists for ischemic events (15, 25) . In fact, the incidence of ischemic events was similar in patients with low and normal platelet reactivity, suggesting that below the safety threshold of PRU, ischemic events are not further significantly reduced.
J A C C : C A R D I O V A S C U L A R I N T E R V E
In addition to that of recurrent ischemic events, the prognostic importance of bleeding complications following PCI has also been established. Ndrepepa et al. (26) have shown that patients with bleeding events within 30 days after PCI have a 3-fold higher risk for 1-year mortality compared with patients without bleeding. Moreover, in a study of 6.995 patients undergoing PCI, periprocedural bleeding complications were significantly associated with increased risk for mortality and adverse cardiac events at follow-up (27) . Recently, 2 studies have sought to define thresholds of platelet reactivity to identify patients at higher risk for bleeding events after PCI. In 1 of these studies enrolling patients undergoing PCI after a 600-mg clopidogrel loading, increased platelet inhibition (Ͻ188 aggregation units), measured with multiple-electrode aggregometry, resulted in a 3.5-fold higher in-hospital incidence of major bleeding (12) . Similarly, the ARMYDA-BLEEDS study (13) showed that low residual platelet reactivity after clopidogrel, as measured with the VerifyNow P2Y12 assay before PCI, is associated with a significantly higher incidence of 30-day major bleeding or entry-site complications, also suggesting a threshold of PRU Յ189 as the optimal cutoff to predict bleeding events. In the present study, we confirm the predictive value of platelet reactivity, as measured with the VerifyNow P2Y12 assay, on the occurrence of bleeding events after PCI, and we found that the optimal cutoff to predict such events was a PRU value Յ178. Similar to ischemic events, a threshold effect seems to be present for bleeding, as no significant difference in the incidence of bleeding events was found between patients with normal and high platelet reactivity.
Using the 2 thresholds for ischemic and bleeding events, we have found a therapeutic window for platelet reactivity, ranging from 179 to 238 PRU, which was associated with the lowest incidence of net adverse events. Despite being relatively small, this range accounts for one-third of the overall population, whereas the remainder of patients was equally distributed between the low and high platelet reactivity groups (Fig. 1) . Although the optimal cutoff for ischemic events (PRU Ͼ239) was very close to the one Boxes extend from the 25th to the 75th percentile, with a line at the 50th percentile (median). Whiskers show the highest and the lowest value. PRU ϭ P2Y 12 reaction units.
described in ARMYDA-PRO (9) and other studies (8, 10, 11) , we found that the optimal cutoff to predict bleeding (PRU Յ178) was lower than the one previously described in ARMYDA-BLEEDS (PRU Յ189) (13) . As expected, the PPV for both the ischemic and bleeding thresholds was very low (15% and 10%, respectively). As predictive values of a test depend on the prevalence of the tested condition, this could be partly explained with the relatively low occurrence of adverse events in a low-risk population of stable patients undergoing elective PCI.
Sibbing et al. (28) have also found a therapeutic window for pre-PCI platelet reactivity, as measured with multipleelectrode aggregometry, identifying the group of patients with aggregation values in the range of 189 to 467 aggregation units as having the lowest risk for the occurrence of both bleeding and ischemic events. However, in this analysis, only in-hospital bleeding and 30-day ST were considered. Recently, Campo et al. (25) have also found a therapeutic window for platelet reactivity measured with the VerifyNow P2Y12 assay (between 86 and 238 PRU). However, in this study, platelet reactivity was measured 30 days after PCI, and the adverse events occurred within the first month were excluded from the analysis. Moreover, a different definition for bleeding events, including both TIMI and BleedScore classifications, was used, compared with the present study.
According to our results, pre-PCI evaluation of platelet reactivity carries important prognostic information and may guide the therapeutic approach to those patients that do not fall within the described therapeutic window. In particular, in patients with a low response to clopidogrel and higher ischemic risk, more aggressive antiplatelet strategies might be useful in obtaining platelet reactivity values that fall within the desired range. These include higher clopidogrel doses, the use of inducers of clopidogrel metabolism (i.e., cilostazol), or newer, more potent P2Y 12 receptor blockers. Although 1 recent study that did tailor antiplatelet therapy by doubling the clopidogrel dose in patients with low response using VerifyNow P2Y12 results did not show any significant benefit (29) , further studies are necessary to clarify this issue (30) . On the other hand, in patients with increased response to clopidogrel and higher bleeding risk, besides deferring PCI until platelet reactivity falls within the desired range, individualized preventive measures could also be indicated (i.e., restricted use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents, more extensive use of the radial approach, bivalirudin, and gastroprotective agents). Study limitations. By study design, we aimed to identify a group of patients with intermediate platelet reactivity presenting the lowest incidence of adverse clinical events among our total population of patients undergoing PCI. This approach implies that the set of patients used to test the hypothesis corresponds to the validation set. The absence of an independent validation set represents a limitation of this study.
Conclusions
This study, using the VerifyNow P2Y12 assay, identified a therapeutic window for platelet reactivity that defines a group of patients at lower risk for both ischemic and bleeding events. Adjunctive measures may be beneficial in patients with higher or lower platelet reactivity in order to improve clinical outcomes after PCI. Larger studies, possibly with longer followup, are warranted to test this hypothesis. CI ϭ confidence interval; OR ϭ odds ratio. Mangiacapra et al. Therapeutic Window for Platelet Reactivity Pre-PCI
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